Donor-Specific Antibodies Targeting a Repeated Eplet Mismatch and Outcome After Kidney Retransplantation
Transplant International · 29.11.2024 · 37
DOI: 10.3389/ti.2024.13639 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, online erschienen am 29.11.2024. Verfasst von Caroline Arches und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculté de Médecine, Sorbonne Universités, Paris, France. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, Graft Survival, HLA Antigens. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kidney retransplantations are associated with an increased risk of rejection and reduced graft survival compared to first transplantations, notably due to HLA sensitization. The impact of repeated eplet mismatches on retransplantation outcome has not been investigated. We retrospectively assessed the risk of antibody-mediated rejection (ABMR) and graft loss associated with preformed DSA targeting Repeated Eplet MisMatches (DREMM) in sensitized patients undergoing kidney retransplantation. We included 45 retransplanted patients with preformed DSA against the second donor. We determined HLA incompatibilities at the eplet levels, and the eplet target of the DSA using HLAMatchmaker ® . Repeated mismatches were more frequent at the eplet (87%) than at the antigenic level (22%), but were not associated with the risk of ABMR. The eplet specificity of the DSA revealed that 60% of patients (n = 27) had DREMM. The presence of DREMM was associated with a higher frequency of ABMR (70% versus 28%, P = 0.005) and with a lower death-censored graft survival (log-rank test, P = 0.01). However, in multivariate Cox model, we could not show that DREMM were associated with the risk of ABMR. In conclusion, this study suggests that identifying DREMM may be an interesting clinical tool, however further larger studies are necessary to precise their exact predictive value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculté de Médecine, Sorbonne Universités, Paris, France.
- Department of Nephrology-Dialysis-Transplantation, Bicêtre Hospital, Assistance Publique des Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
- Immunology and Histocompatibility Laboratory, Saint-Louis Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France.
- Department of Nephrology and Transplantation, Necker Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France.
- Department of Nephrology, Foch Hospital, Suresnes, France.
- Institut National de la Santé et de la Recherche Médicale U1184 Centre de Recherche en Immunologie des Infections Virales et des Maladies Auto-Immunes, Le Kremlin-Bicêtre, France.
Zitieren
APA
Arches, C., Usureau, C., Anglicheau, D., Hertig, A., Jalal-Eddine, A., Zaidan, M., Taupin, J. L., & Snanoudj, R. (2024). Donor-Specific Antibodies Targeting a Repeated Eplet Mismatch and Outcome After Kidney Retransplantation. Transplant International, 37. https://doi.org/10.3389/ti.2024.13639
Vancouver
Arches C, Usureau C, Anglicheau D, Hertig A, Jalal-Eddine A, Zaidan M, et al. Donor-Specific Antibodies Targeting a Repeated Eplet Mismatch and Outcome After Kidney Retransplantation. Transplant International. 2024;37. doi:10.3389/ti.2024.13639
BibTeX
@article{Arches2024,
author = {Arches, Caroline and Usureau, Cédric and Anglicheau, Dany and Hertig, Alexandre and Jalal-Eddine, Arwa and Zaidan, Mohamad and Taupin, Jean-Luc and Snanoudj, Renaud},
title = {Donor-Specific Antibodies Targeting a Repeated Eplet Mismatch and Outcome After Kidney Retransplantation},
journal = {Transplant International},
year = {2024},
volume = {37},
doi = {10.3389/ti.2024.13639}
}
EUVIMED